Table 1.
Characteristics among men with prostate cancer (n = 434) in the Health Professionals Follow-up Study who underwent radiation therapy
| Median Age at diagnosis (IQR) | 72 yrs (68 – 76 yrs) |
|
| |
| Median Age at XRT (IQR) | 72 yrs (69 – 77 yrs) |
|
| |
| PSA at diagnosis, N (%) | |
| <10 | 312 (73) |
| 10–20 | 95 (22) |
| 20–50 | 22 (5) |
| Unknown | 5 |
|
| |
| Gleason score, N (%) | |
| <7 | 292 (69) |
| 7 | 95 (22) |
| >7 | 36 (9) |
| Unknown | 11 |
|
| |
| Clinical Stage, N (%) | |
| T1/T2 | 418 (98) |
| T3 | 10 (2) |
| Unknown | 6 |
|
| |
| Radiation Treatment, N | |
| External beam | 243 (56) |
| Brachytherapy | 143 (33) |
| External beam + Brachytherapy | 48 (11) |
|
| |
| Adjuvant/neoadjuvant ADT, N (%) | 173 (40%) |
|
| |
| Reached composite outcome, N (%) | 100 (23%) |
| Biochemical recurrence only | 77 (77%) |
| Lethal prostate cancer only | 9 (9%) |
| Biochemical recurrence/lethal prostate cancer | 14 (14%) |
|
| |
| Variation in RNASEL | |
|
| |
| rs486907 (R462Q), N (%) | |
| CC | 177 (41) |
| CT | 195 (45) |
| TT | 57 (13) |
| Unknown | 5 |
|
| |
| rs627928 (D541E), N (%) | |
| AA | 134 (32) |
| AC | 208 (49) |
| CC | 82 (19) |
| Unknown | 10 |
|
| |
| rs12757998 (%), N (%) | |
| GG | 218 (51) |
| GA | 176 (42) |
| AA | 30 (7) |
| Unknown | 10 |
Abbreviations: yrs – years; IQR – interquartile range; XRT – radiation therapy; PSA – prostate-specific antigen; ADT – androgen deprivation therapy; R – arginine; Q – glutamine; E – glutamic acid; D – aspartic acid; C – cytosine; T – thymine; A - adenine